Table 2.

Future areas of masked hypertension research

Who is at risk for developing masked hypertension? Which individuals with masked hypertension are at the highest risk for adverse events? What time periods (daytime, 24-hour, and/or nighttime) should be used to diagnose masked hypertension and is it appropriate to use the same criteria for all populations What strategies should be used to monitor out-of-clinic BP (ABPM, HBPM or both)? What are cost-effective screening strategies to diagnose masked hypertension and monitor response to treatment? Should subclinical cardiovascular disease or target organ damage be a screening criteria for masked hypertension prior to conducting ABPM or HBPM? What are the effects of lifestyle and/or pharmacologic treatment on reducing target organ damage, CVD events and mortality in persons with masked hypertension?